Nuclear reactors continue to play an important role in providing radioisotopes for nuclear medicine [1] [2] . Most reactor-produced radioisotopes are "neutron rich" "and decay by betaemission and are thus of interest for therapeutic applications (Table 1) . Routine clinical applications with therapeutic radioisotopes, include cancer therapy and bone pain palliation [3] [4] ( Table 2) , and require reliable availabilityof the required radioisotopes at reasonable costs. Other important applications include the irradiation of tumors, which has been described extensively elsewhere, and the treatment of rheumatoid arthritis ('ladlonuclide synovectomy"). In addition, an important new application using both reactor-produced gamma-and in paticular, beta-emitting radioisotopes, is for the inhibition of arterial restenosis following high pressure balloon angioplasty, primary for the coronary vessels [5] [6] [7] [8] . Radionuclide generators (Table 3) prepared from reactor-produced radioisotopes are of particular interest since repeated elution can inexpensively provide many patient doses. This aspect is expected to be especially important for providing a source of radioisotopes to remote sites, especially in developing regions, which involve long distances and expensive distribution costs. A major growth area in nuclear medicine is therapy, with both unsealed sources and tissue-targeted radiopharmaceuticals, and there is thus a rapidly increasing requirement for therapeutic radioisotopes, most of which are reactorproduced. Whh the increasing use of beta-emitting radioisotopes in nuclear medicine, oncology and intewentional cardiology, nuclear reactors will play an increasingly important role in providing radioisotopes for these applications. A recent review [9] has summarized the reactors which are available internationally (297 as of 1994) and those which are used for medical radioisotope production. Although a variety of research reactors are operating throughout the world, including several which have moderate to high thermal neutron flux (Table 4) , the general trend is that most of these reactors are 20-30 years old, and no new reactors are currently planned, for example, for construction in the U.S. Fortunately, several new reactors are planned for construction in Canada (Nordion; Maple X 1 and 2; expected to begin operation in the year 2000 at 10MW), Australia (HIFAR II; ANSTO; 2005; 10 MW) and Germany (FRMI~Munich; 2005; 20MW) and will hopefi.dlyrepresent importad new resources for medical radioisotope production. The goal of this paper is to briefly review the production and use of several reactor-produced radioisotopes of current interest for bone pain palliation and intravascular brachytherapy, and to discuss the role of the ORNL High Flux Isotope Reactor (HIVl?) for the production of many of these radioisotopes. Current upgrades of the HEIR are also described increased production capabilities of tin-117VZand tungsten-188.
which will in particular permit
Reactor-Produced Radioisotopes for Bone Pain Palliation
One major current medical use of reactor-produced radioisotopes is for the treatment of painful skeletal metastasis which is oflen encountered in patients with primary tumors of the breast, prostate and lung [34] . Although many of these patients are ofien "end-stage", the quality of Me can be significantly improved with the cessation of intractable pain. The use of therapeutic radioisotopes which locdlze at metastatic sites has been found to be an inexpensive and effective method for treatment of pain, especially for multiple sites for which the use of external beam irradiation is impractical. Such palliative treatment of patients with advanced metastatic disease to the skeleton can dramatically improve their quality of life, and is important application which has many advantages over traditional use of analgesics and external radiation. There are currently several metastatic-targeted agents radiolabeled with various therapeutic radioisotopes which are in various stages of clinical investigation [3] [4] . Most radioisotopes used for bone pain ptilation are reactor-produced (Table 2) . Key examples produced by single neutron capture of enriched targets include rhenium-1 86 and samarium-153. In addhion, generator systems which provide therapeutic daughter radioisotopes from the decay of reactor-produced parent radioisotopes are also of interest. One important example is rhenium-188, available from generators via decay of reactor-produced tungsten-188. Tin-117m is an example of a reactor-produced radioisotope which decays with the emission of low energy conversion electrons rather than by~-decay. Each of these agents andlor radioisotopes has specific advantages and disadvantages, however, and the "ideai" agent for bone pain palliation has not yet been identified.
Reactor-Produced Radioisotopes for Vascular Brachytherapy
An important new therapeutic strategy in the realm of interventional cardiology is the use of beta and gamma-emitting radioisotopes for intravascular brachytherapy (llZ?) for the inhibition of coronary restenosis following high pressure percutaneous transhuninal coronary balloon angioph.sty (H'CX). Most of the radioisotopes for this application are reactor-produced and the generator-derived beta-erqitting radioisotope rhenium-188, is in partciular expected to have important applications. An emerging application we have recently proposed [5] [6] [7] [8] which is expected to have very important applications is the use of solutions of rhenium-188 agents for the inhibition of coronary artery restenosis following PTCA. This new and u~que approach involves the low pressure intracoromuy balloon expansion using solutions of rhenium-188, since solutions offer the most uniform vessel wail radiation dose delivery system. The chemical species which are being evaluated for this application inciude rhenium-188-perrhenate and the rhenium-l88-MAG3 agent (MAG3 = mercaptoacetyltriglycine) and both these chemical excreted via the urinary bladder in the unlikely event of balloon rupture.
The ORNL High Flux Isotope Reactor (HFIR)
species are rapidly
Research reactors represent important facilities for production of a wide spectrum of radioisotopes for various therapeutic applications. The HFI. is located at the Oak Ridge National Laboratory (ORNL) in Oak Ridge, Tennessee, and has the highest steady-state thermal neutron flux and the highest power density available in the world (Figures 1 and 2 ). The HFIR was originally designed for the production of transuranium radioisotopes, primarily californium-252 and today is a major resource for nuclear medicine research, and permits the production of very large amounts of high speciiic activity radioisotopes which cannot be produced at many other sites (Table 1) advantage of this desi~since it permits removal of the targets from the PTP tubes in the HFIR pool area, with subsequent transportation to the hot cell processing area using the same carrier which is currently in use. A special "carousel" unit is currently being installed in the HFIR pool for loading and unloading the HT targets from the the PTP units (Figure 4 ).
Examples of Reactor Production Pathways for Therapeutic Radioisotopes
Single Neutrofi Capture l?roduction Pathway -Several usefid therapeutic radioisotopes can be produced by this route (Tables 1) . Rhenium-186 is a key example of a radioisotope of cument interest which is produced by neutron capture of enriched rhenium-185. Although the neutron capture cross section is relatively high, very high specific activity rhenium-186 is required for antibody labelirg which may not be possible with many low flux reactors. However, low specific activity rhenium-186 can be used for preparation of phosphonates (Table 2) for palliative treatment of bone pain from cancer. Because of the high thernxd neutron cross-section for the rhenium-185(n,y)rhenium-186 reaction, HFIR irradiation of enriched rhenium-185 yields high specific activity rhenium-186. Typical production values for a one week irradiation in the HFIR are 13-15
Curies/mg rhenium-185. Samarium-1 53 is another example of a~--emitting therapeutic radioisotope for bone pain palliation which can be produced in large amounts with high specific activity in even moderate flux reactors. One agent which is currently under development is the Sm-153-E.DYA4P phosphonate analogue. Palladium-l 03 can be reactor-produced by irradiation of enriched palladium-102 and represents a major radioactive implantation device for the treatment of prostatic carcinoma. Iodine-125 is manufactured and used for the same application.
.
Therapeutic Radioisotopes Available From Beta-Decay of Reactor-Produced Radioisotopes -
Another usefil approach which provides carrier-free radioisotopes for therapy is by "batch" chemical separation of the product formed by~--decay of the reactor-produced parent. Examples produced via this route include silver-111, arsenic-77 and gold-199. Silver-1 11 is readily obtained by anion exchange chromatographic separation of palladium-l 11, and the 7.47 day half-life readily permits shipment to other sites. Silver can be complexed %th iimctionalized tetraazaheterocycles for attachment to antibodies or other therapeutic agents. Arsenic-77 is readily separated from the germanium-77 reactor product and has chemistry similar to phosphorus, permitting preparation of arsenates and other potentially usefi.dspecies. The last example, gold-199, has been of interest for many years and in carrier-free form can be attached to antibodies.
neutron capture process arepropoflional tothesquwe of the neutron flux, thereactor neutron -.. flux is an important factor for this common reaction pathway. Two radioisotope parents produced by this process which are of current interest for generator systems (Table 3) carrier-flee hohnium-166 (containing no holmium-166nz), which is separated by HPLC methods and is currently used for radiation synovectomy, etc. Rhenium-188 is readily separated from tungsten-188 on alumina (vzde infia) and is of interest for a variety of therapeutic applications.
HFIR Production by the Inelastic (n,n') Route From Enriched Tin-117 -Tin-117nz is produced with relatively low specific activity (5-6 mCi/mg) by neutron irradiation of enriched tin-116. Specific activity can be increased in the HFIR by a factor of about 3 by the tin-117(n, n')tin117nz inelastic route (20-22 mCi/mg) [11] . In contrast to the other radioisotopes of current interest for palliation, tin-117nz decays by conversion electron emission. The low energy conversion electrons travel only a very limited distance in tissue, which may preclude potential bone marrow depression which can be a Iiiting factor with high energy~--emitting radioisotopes, is precluded. Potential advantages of tin-117nz are the absence of high energy beta particles, the emission of a gamma photon of nearly optimal energy for imaging, and high metastatic uptake.
Production of tin-117nz in nuclear reactor involves radiative capture by the (n,y) route by irradiation of enriched tin-116, or via the inelastic (n,n'y) route by irradiation of enriched tin-117.
We have evaluated both these routes in detail using the ORNL HFIR [11] , where specific activity values of 8-10 mCi/mg from enriched tin-117 tier a long irradiation time (1 cycle =24 days) are routinely obtained. The metallic powder target is shipped directly to customers for processing and preparation of the Sn-117m(IV)-DTPA complex.
Radionuclide Generators Requiring Reactor-Produced Parents
Radionuclide generators continue to play an important role in nuclear medicine [12] [13] [14] .
Two radionuclide generators which are based on reactor-produced parent radioisotopes which are of current major interest (Table 3) provide dysprosium-l 66 (dysprosium-165/dysprosium-166)
[10] and rhenium-188 (tungsten-188/rhenium-188) [15] [16] [17] [18] [19] .
Rhenium-188 -Rhenium-188 is available carrier-free &om a tungsten-188/rhenium-188 generator.
The generator which we have developed and optimized at ORNL is a chromatographic system which uses alumina as the adsorbent. Since one of the major issues facing the health care industry is the reduction of costs, a major important advantage for use of rhenium-188 is the inexpensive, ready availability from the generator which has a very long usefi,d shelf-life of several months [15] [16] [17] [18] [19] . Another advantage is the emission of the 155 keV gamma photon for imaging. There are several rhenium-188-labeled agents which are currently under clinical investigation for bone palliation which include rhenium-188-HEDP and rehnium-188(v)-LYMSA (Table 3) . We have demonstrated that large, clinical-scale generators loaded with high levels of tungsten-188(> 1 Curie) provide reproducible high rhenium-l 88 yields of 75-85 %/bolus and low tungsten-188 parent breakthrough (< 104) for periods of several months [15] [16] [17] [18] [19] . These studies have demonstrated that the costs of rhenium-188 will be very low on a bolus or unit does basis.
Probably the most cost effective approach for using the tungsten-188/rhenium-188 generator would be its use the in a hospital or centralized radiophannacy, and it remains to be seen if this will be possible. 
Summary and Conclusions
Research reactors continue to represent important facilities for production of therapeutic radioisotopes for bone pain palliation. The very high flux of the ORNL HFIR is a unique capability and this reactor represents an important resource for the production of variety of medical radioisotopes, which require a very thermal neutron flux, including several of current interest for bone pain palliation, such as tungsten-188 (i.e. rhenium-188) and tin-117m. 
